Getting Up-to-Speed on New Data
Produced in collaboration with CLL Society and the Leukemia & Lymphoma Society.
This patient education activity is supported by an educational grant from Pharmacyclics LLC, an AbbVie Company, and Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC.
Join us for a new educational session designed to help patients with chronic lymphocytic leukemia (CLL) understand current and emerging therapies, manage side-effects, and improve communication with their health care teams. A dynamic panel featuring a CLL patient, a hematology/oncology expert, and a patient advocate will review real-world patient experiences and discuss what long-term research findings on BTK inhibitors and other treatments mean for patient quality of life.
Topics discussed include:
- Defining goals of therapy and quality of life with CLL
- Managing adverse events of BTK inhibitors
- Ensuring mind-body health
- Caregiver health and why it’s a priority
After watching this program, you’ll:
- Understand what real-world and long-term data are, and how they can define care and quality of life for patients with CLL
- Improve your ability to identify and assist in managing side effects in a timely manner
- Learn patient-caregiver best practices to remain healthy throughout the CLL journey
- Have resources from CLL patient-advocacy organizations
Managing Adverse Events of BTK Inhibitors - What, When, How, and Who
Tips to Stay on the Patient/Caregiver 'A Game'
Got a Question? We've got answers
Jennifer Woyach, MD
Professor, The Ohio State University
Jennifer Woyach, MD, is a Professor with Tenure in the Division of Hematology at The Ohio State University (OSU), the section chair of Chronic Lymphocytic Leukemia (CLL), and co-leader of the Leukemia Research Program. Dr. Woyach is a physician scientist focused on translational research in CLL. Her laboratory interests include experimental therapeutics in CLL with a focus on signaling pathways and kinase inhibition. Clinically, Dr. Woyach is the principal investigator for multiple early-stage clinical trials investigating novel targeted therapies for CLL and other hematologic malignancies. She chaired the NCTN Phase III study A041202 which showed that ibrutinib is superior to standard chemoimmunotherapy in older patients and that rituximab does not improve PFS when added to ibrutinib.
Therese Conlin’s CLL journey began when a routine health screen and blood test triggered her CLL diagnosis. She received treatment after 7 years, when her CLL had progressed to a point where the cancer cells were interfering with healthy cells. Using the information gathered from her healthcare team and her research about CLL, Therese made the decision to enter a clinical trial in 2018. The trial studied the combination of 2 FDA-approved targeted therapies used to treat patients with CLL. She completed the 3-year trial with positive results and is presently, successfully managing her CLL under the care of her long-time CLL specialist. Therese is an active member of a regional CLL Society Support Group and is appreciative of the wealth of information available within the CLL community.
Jennifer Wilson, LCSW-R
Senior Information Specialist
The Leukemia & Lymphoma Society
- What to Know About the Use of CAR-T Therapy
- Overview of CLL Society Programs
- Test Before Treat
- Aligning on Patient and Provider Goals
- Caring for the Caregiver
- Caregiver Resource Guide
- The Leukemia & Lymphoma Society - Each New Day Booklet
- The Leukemia & Lymphoma Society - Managing Stress
- The Leukemia & Lymphoma Society - Nutrition Handbook
- The Leukemia & Lymphoma Society - Survivorship Booklet